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Abstract
Background: The advent of anti-tumor necrosis factor-α (TNFα) drugs has changed the course of ankylosing
spondylitis (AS). While data are available concerning the long term effectiveness of single anti-TNF agents, little
has been published about predictors of treatment response in AS. The aim of this retrospective study was to
evaluate the survival, effectiveness, and safety of infliximab over a 5-year period and to identify predictors of
disease outcome.
Methods: Seventy AS patients attending the Rheumatology Clinic of the University of Padua who were treated
with intravenous infliximab at 0, 2, 4 weeks and then every 6, 8, or up to 16 weeks were studied retrospectively.
Demographic information, laboratory inflammatory and disease indices (BASDAI, BASFI, BASMI) were collected
(at baseline, 3, 6, 12 months and once a year thereafter). Clinical improvement, drug tolerability, adverse events/
side effects and causes leading to discontinuation were recorded.
Results: Infliximab caused a rapid, persistent improvement at all the assessment times in the BASDAI 50 (71.4 %) and
ASDAS scores (97.1 % in ASAS20, 80 % in ASAS40, 80 % in ASAS5/6), and already within 6 months of beginning
treatment in 50 % percent of the patients. The other 50 % withdrew because of: adverse events (12 = 34.3 %), side
effects (5 = 14.3 %), drug inefficacy (12 = 34.3 %), spontaneously (4 = 11.4 %). Those who did not respond were
prevalently females (34.3 % vs 17.1 %).
Conclusion: Factors such as female sex, use of steroids, persistently high inflammatory levels, BASFI and BASDAI
indices were found to be negative predictors of treatment response. Infliximab was found to be safe, effective and
well-tolerated; it elicited satisfactory long term response and drug survival rates.
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Background
Ankylosing spondylitis (AS), a prototype of the spondy-
loarthritis (SpA) family, is a chronic, progressive, axial
inflammatory disease mainly involving the spine and the
sacroiliac joints [1], as well as other sites of the axial
skeleton such as anterior chest wall joints [2]. Since the dis-
ease can lead to severe, chronic pain and discomfort [1, 3],
treatment should be initiated as early as possible to prevent
skeletal deformity and physical disability [4]. In the past
(until’90s), few effective therapies were available and were
limited for the most part to regular physical activity and
non-steroidal anti-inflammatory drugs (NSAIDs) [1, 5, 6].
Disease-modifying antirheumatic drugs (DMARDs) and
corticosteroids, which are quite effective in other chronic
inflammatory diseases such as rheumatoid arthritis (RA),
appear to have only a limited or no effect on the course of
AS [1, 6–9].
The advent of anti-Tumor Necrosis Factor-α (TNFα)
agents (adalimumab, etanercept, infliximab and golimu-
mab) has constituted a breakthrough in the management
of AS patients, especially in the case of persistently active
forms [1, 10–17]. Anti-TNFα agents have been found to
produce clinical, functional, biological, as well as quality of
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life improvements. Trials with infliximab and other anti-
TNFα agents have, in fact, demonstrated a remarkable im-
provement in AS patients, and their efficacy and safety
have been confirmed by a number of randomised, open-
label, controlled studies [17–22]. These results need, how-
ever, to be confirmed by further studies focusing on some
treatment-related aspects and patients’ real life experience.
While single center studies have many limitations with re-
spect to multicenter studies or registries, they have the ad-
vantage of studying a more homogeneous population and
of thus preventing at least one confounding factor. The
aim of this retrospective single center study was to evalu-
ate the effectiveness, safety and the long-term drug sur-
vival of infliximab in AS patients over a 5-year treatment
period and to identify predictors of disease outcome.
Methods
Study population
Seventy AS outpatients diagnosed between 2003 and
2010 in accordance with the modified New York criteria
[23] and attending the Rheumatology Clinic of the Univer-
sity of Padova Medical Center were enrolled in this retro-
spective study. This study was approved by the ethics
committee of Padova University Hospital. All of the pa-
tients provide written informed consent for participation
in this study. Inclusion criteria were: age >18 years and an
inadequate response (no response or lack of tolerance) to
previous NSAIDs. Exclusion criteria were: signs or symp-
toms of latent or active tuberculosis, chronic or clinically
severe infection, malignancy or congestive heart failure.
All the recruited patients were treated with inflixi-
mab, which was administered intravenously (3–5 mg/kg/
body weight) at 0, 2, 6 weeks and every 4 weeks thereafter
for a 5-year period. Whenever drug scheduling produced
an optimal treatment response, the time interval be-
tween drug infusion was prolonged to 6, 8 or to as
many as 16 weeks. In addition to pharmacological ther-
apy, all patients followed a home-based exercise pro-
gram recommended by the specialized physiotherapist
who collaborates with our unit.
Clinimetric, laboratory tests, assessment questionnaires,
and outcome measures
All the patients underwent regular clinical and clini-
metric evaluations prescribed by a specialized rheuma-
tologist. Demographic data and assessment scores at
baseline (0 M), at 3 months (3 M), at 6 months (6 M),
and once a year thereafter for a 5-year period were sys-
tematically collected.
The instruments utilized included the Bath Ankylosing
Spondylitis Disease Activity Index (BASDAI) which is the
most commonly used instrument to measure and evaluate
the inflammatory activity of AS (values expressed from 0
to 100). Considered the gold standard to assess physical
function in AS patients and commonly used to screen
candidates for anti-TNF medication the Bath Ankylosing
Spondylitis Functional Index (BASFI), is a self-reported,
validated, outcome measure. Active disease was identified
by the BASDAI and/or BASFI score > 4 [24, 25]. Spinal
mobility was measured using the Bath Ankylosing Spondi-
litis Metrology Index (BASMI). Pain and global assess-
ment were measured using the Visual Analogue Scale and
patient global assessment (VAS and VASg) whose scores
range from 0 to 10. Laboratory measures of inflammation,
such as C-reactive protein (CRP) and erythrocyte sedi-
mentation rate (ESR), were regularly assessed in all the pa-
tients (normal values for our laboratory: <0.6 mg/dL for
CRP and <20 mm/hour for ESR). Clinical improvement in
the patients who continued to receive infliximab through-
out the study period was also assessed using the Ankylos-
ing Spondylitis Assessment Study Group (ASAS) criteria
20 and 40 % and the ASAS 5/6 response criteria [26]. The
ASAS20 defines improvement as at least 20 % (or an abso-
lute improvement of at least 10 units on a scale of 0–100)
in three of the following domains: patient’s global assess-
ment of disease activity, pain, function (BASFI score) and
morning stiffness (considered the average of the last two
questions on the six-question BASDAI regarding morning
stiffness). The ASAS40 defines improvement as at least
40 % or an absolute improvement of at least 20 units on a
0–100 mm scale in at least three out of the four domains,
without worsening in the remaining one. The “ASAS five
out of six criteria” defines improvement as a 20 % amelior-
ation in any of five of the following six domains: the four
domains used for ASAS 20 % and ASAS 40 %, acute phase
reactants and spinal mobility, as assessed by the BASMI
score.
Statistical analysis
The Mann–Whitney U test was used to compare the clin-
ical (BASDAI, BASFI, BASMI, VAS, VASg) and inflamma-
tory indices (CRP, ESR) of the patients who continued to
take infliximab throughout the study period and those
who did not at time 0 (0 M) and 60 months later (60 M).
The Friedman Repeated Measures test followed by the
Dunn's Multiple Comparison Test were used to evaluate
the pattern in these parameters over time (at baseline, at
3 M, at 6 M, at 12 M and once a year there after). A
p value less than 0.05 was considered significant.
Results
Out of the 70 originally recruited AS patients, half (35 =
50 %) continued to take infliximab for the entire 5-year
study period. At baseline, higher BASDAI and BASFI
scores and mean CRP levels confirming active disease
was found in both those who later had a positive re-
sponse to the therapy (responders) as well as in those
who did not (non-responders). Twenty-nine (82.9 %) of
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the responders were male (mean age 50.4 ± 12.5; mean
disease duration 17.9 ± 10.6 years); the majority of the
non-responders were female (34.3 % vs 17.1 %). At base-
line (0 M) the characteristics of the responders were
similar to those of the non-responders -except for pred-
nisone intake and the VASg score -, which were higher
in the latter with respect to the former (Table 1).
Half (35/70) of the patients discontinued therapy due
to insufficient response or adverse events to infliximab
during the 5-year study period. There were instead 54
(77.1 %) patients still taking infliximab at one year, 49
(70 %) at 2 years, 40 (57.1 %), at 3 years and 37 (52.9 %)
at 4 years. The causes leading patients to withdraw were
evenly distributed over the 5-year study period (Fig. 1) and
included: therapeutic ineffectiveness (in 12 = 34.3 %), ad-
verse events - such as injection site reactions, headache,
hypertensive crisis, tachycardia, vertigo, abdominal pain -
(in 12 = 34.3 %), several site effects and in 4 (11.4 %) cases
the patient moved away (Fig. 1). There was a statistically
significant improvement in all of the indices over the study
period in the responders. The patterns of the various study
parameters over the 5-year period are outlined and
compared in Fig. 2. There was a significant decrease in
the BASDAI, BASFI, ESR indices in the responders
with respect to the non-responders: at the end of the
study the BASDAI was, in fact, 25.8 ± 18.5 and 43.1 ± 21.7
(p = 0.0347), the BASFI was 15.8 ± 12.2 and 45.5 ± 26.1
(p = 0.0009), the ESR was 11.5 ± 8.74 and 21.9 ± 15.8 (p
= 0.0323), respectively. There was also a slight but not
statistically significant improvement in the CRP and
BASMI values in the responders (Fig. 2). At 3 M, the BAS-
DAI and the ASAS scores in the responders were already
beginning to show an initial positive response and at 6 M
there was a significant, clear improvement which was
maintained throughout the 5-year period (Fig. 3). After
5 years of treatment 25 (71.4 %) achieved 50 % improve-
ment in the BASDAI, 34 (97.1 %) attained the ASAS 20 %,
28 (80 %) attained the ASAS 40 %, and 28 (80 %) achieved
Table 1 Demographic, clinical, and biohumoral characteristics
at baseline of the 70 AS patients who were treated with
infliximab treatment and classified into two groups: those
still taking the drug (responders) or not taking the drug
(non-responders) at the end of the five year period
Responders Non-responders p*
N 35 35
Male, N (%) M 29 (82.9 %) M 23 (65.7 %) ns
Age (years) 50.3 ± 12.5 48.5 ± 11.0 ns
DiseaseDuration (years) 17.9 ± 10.6 16.3 ± 9.3 ns
MTX intake, N (%) 15 (42.9 %) 12 (34.3 %) ns
Sulfasalazine, N (%) 3 (8.6 %) 5 (14.3 %) ns
Prednisone intake, N (%) 5 (14.3 %) 14 (40 %) <0.005*
Uveitis, N (%) 1 (4.1 %) 1 (4.1 %) ns
IBD, N (%) 1 (4.1 %) 0 ns
NSAIDS, N (%) 29 (82.9 %) 27 (77.1 %) ns
ESR (mm/H) 21.5 ± 18.3 31.0 ± 25.1 ns
CRP (mg/dL) 1.9 ± 1.6 1.7 ± 1.5 ns
BASDAI 59.5 ± 15.3 59.9 ± 19.6 ns
BASFI 47.1 ± 16.8 52.2 ± 25.1 ns
BASMI 5.9 ± 1.3 5.4 ± 1.6 ns
VAS 64.9 ± 16.9 62.9 ± 18.8 ns
VASg 50.5 ± 21.4 61.1 ± 19.0 0.05*
N number, MTX Methotrexate, IBD Inflammatory Bowel Diseases, NSAIDs Non
Steroidal Anti-Inflammatory Drugs, ESR Erytrocyte Sedimentation Rate, CRP
C-Reactive Protein, BASDAI Bath Ankylosing Spondylitis Disease Activity Index,
BASFI Bath Ankylosing Spondylitis Functional Index, BASMI Bath Ankylosing
Spondilitis Metrology Index, VAS Visual Analogue Scale pain, VASg Visual
Analogue Scale global disease activity
Data expressed as mean ± standard deviation, unless otherwise indicated
*Mann Whitney test
Fig. 1 Flow chart of the five year period
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the ASAS 5/6. Clinical improvement was also associated
to lower ESR and CRP: CRP levels fell from 1.9 ± 1.6 at
0 M to 0.8 ± 1.5 at 60 M, and ESR levels fell from 21.7 ±
18.2 at 0 M to 11.5 ± 8.7 at 60 M (Fig. 2 and Table 2).
Interestingly, only two patients (2.8 %) had uveitis, one of
these responded to inflximab treatment and the other did
not. The frequency of uveitis episodes fell from 3 times/year
to 1 time/year for the first year of treatment and to 0 time/
year for the following years in the responder. Only one
non-responder had a single episode of uveitis in the entire
study period and he was successfully treated with topical
steroids. Only one of the patients had AS associated to in-
flammatory bowel disease (Crohn disease) and was treated
with infliximab; his response both with regard to articular
as well as bowel symptoms was good (Table 1).
Forty-five (64.3 %) of the patients developed infections,
the severity of which ranged from mild (requiring tem-
porary interruption of treatment) to severe (requiring
permanent suspension of treatment) (Table 3).
Drug survival was calculated as the number of days that
the individual patients took the drug. The start date was
the day the first dose was taken and stop date was the day
treatment was interrupted. Temporary interruptions e.g.,
due to infections or surgery of ≤3 months’ duration were
acceptable according to our study protocol. In two cases
the severity of infection (severe scalp infection and tubal
Fig. 2 Serological, clinical and functional parameters during the 5-year study period. a CRP, b ESR, c BASDAI, d BASFI, e BASMI in completers
(n = 35) and in discontinuers (n = 35). Mann Whitney test: p1 = M0 responders vs M0 non responders; p2 = M60 responders vs M60 non-reponders
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abscess) necessitated permanent discontinuation of inflixi-
mab treatment (Fig. 1). Infliximab survival (percentage of
responders) over the 5 study period is outlined in Fig. 4.
Thirty-one (44.3 %) of the 35 responders were able to pro-
long the time interval between infusions (the mean time
interval was 7.5 ± 4.1 weeks).
Discussion
In agreement with other reports, these data confirm that
infliximab therapy is safe, tolerable and effective in AS
patients [10, 11, 16–22, 27, 28]. The rapid stable, sub-
stantially positive therapeutic effect of infliximab treat-
ment in most patients with active AS has recently been
demonstrated by an open-labeled multicenter study which
described a statistical improvement in the ASAS criteria
in 84.8 % of the patients who completed the trial [29].
Data confirming infliximab’s efficacy and safety have also
been reported by some registry-based studies. The Czech
national ATTRA registry in fact, found a longer adherence
to anti-TNFα therapy due to clinical improvement and a
prolonged, satisfactory response, in particular to inflixi-
mab, in AS with respect to RA patients [30]. The TRASD-
IP registry also described the positive effect that infliximab
treatment had on patients’ quality of life [31]. According
to recent results based on the Danish DANBIO registry,
out of 1436 AS patients who started anti-TNFα treatment,
30 % later switched to a second and 10 % to a third bio-
logical drug [32]. The authors also reported that after
2 years of treatment 52 % of the switchers and 63 % of the
non-switchers achieved treatment response and that the
majority of switchers were women [33].
Our study also confirmed that the female gender seems
to be a negative predictor of drug response and disease
outcome. Other values which differed at baseline between
the responders and the non-responders were the global
disease activity score (VASg) and steroid intake, which can
be interpreted as additional negative predictors.
Fig. 3 Clinical outcome in responders (n= 35;50 %) over the five year
period (expressed in percentage %). M =months; ASAS 20 = Ankylosing
Spondylitis Assessment Study Group 20 %; ASAS 40 = Ankylosing
Spondylitis Assessment Study Group 40 %; ASAS 5/6 = Ankylosing
Spondylitis Assessment Study Group 5/6; BASDAI 50 = Bath Ankylosing
Spondylitis Disease Activity Index 50
Table 2 Serological, clinical, and functional parameters during the five year study period
Variable ESR CRP BASFI BASDAI BASMI VAS VASg
(mean ± SD)
Responders 0 M 21.7 ± 18.2 1.9 ± 1.6 47.1 ± 16.8 59.5 ± 15.3 5.9 ± 1.3 64.9 ± 16.9 50.5 ± 21.4
3 M 13.5 ± 12.8 1.3 ± 1.9 44.5 ± 17.5 54.2 ± 17.3 5.7 ± 1.4 61.3 ± 15.1 45.4 ± 22.1
6 M 10.4 ± 8.8 1.0 ± 1.4 38.1 ± 22.2 46.5 ± 20.1*** 5.6 ± 1.3 55.3 ± 12.4* 40.6 ± 21.6*
12 M 11.9 ± 12.4 1.1 ± 1.4 32.1 ± 20.1** 40.9 ± 19.4* 5.1 ± 1.6*** 41.1 ± 11.9* 35.6 ± 19.9*
24 M 10.9 ± 10.2 1.2 ± 1.9 27.2 ± 17.4* 38.9 ± 20.9* 4.8 ± 1.4* 37.8 ± 10.9* 32.4 ± 17.8*
36 M 14.2 ± 12.6 0.9 ± 1.1 23.4 ± 15.3* 31.4 ± 18.1* 4.7 ± 1.4* 36.2 ± 10.1* 30.5 ± 18.7*
48 M 13.1 ± 8.1 0.7 ± 1.6* 20.4 ± 13.9* 28.2 ± 18.8* 4.5 ± 1.3* 32.6 ± 12.1* 25.2 ± 19.6*
60 M 11.5 ± 8.8 0.8 ± 1.5* 15.8 ± 12.2* 25.8 ± 18.6* 4.2 ± 1.4* 30.8 ± 13.2 20.3 ± 19.8
p 0.087 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Non-responders 0 M 31.0 ± 25.1 1.6 ± 1.5 52.2 ± 25.1 59.9 ± 19.6 5.4 ± 1.6 62.9 ± 18.8 61.1 ± 19.0
3 M 22.2 ± 22.6 1.4 ± 1.7 45.5 ± 21.9 55.7 ± 19.1 5.3 ± 1.6 57.2 ± 22.3 59.2 ± 22.9
6 M 21.5 ± 7.1 1.4 ± 1.6 43.2 ± 23.1 53.7 ± 19.9 5.0 ± 1.4 55.4 ± 20.6 60.5 ± 21.1
12 M 22.5 ± 20.4 1.4 ± 1.4 37.1 ± 24.9 23.0 ± 43.9 4.8 ± 1.6 47.8 ± 21.3 49.2 ± 20.0
24 M 17.9 ± 12.9 1.5 ± 3.1 24.9 ± 15.6 39.1 ± 25.6 4.9 ± 1.4 49.7 ± 22.2 55.5 ± 22.0
36 M 22.3 ± 14.1 1.4 ± 1.3 39.6 ± 27.9 38.8 ± 26.9 4.2 ± 2.2 50.2 ± 18.8 52.4 ± 19.7
48 M 23.5 ± 22.7 1.4 ± 2.1 33.4 ± 25.5 35.1 ± 23.3 4.1 ± 1.4 57.3 ± 17.4 60.6 ± 20.1
60 M 21.9 ± 15.8 1.6 ± 2.3 45.5 ± 25.1 43.1 ± 21.7 4.1 ± 1.5 58.2 ± 18.5 65.1 ± 19.8
ESR Erytrocyte Sedimentation Rate, CRP C-Reactive Protein, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASFI Bath Ankylosing Spondylitis Functional
Index, BASMI Bath Ankylosing Spondilitis Metrology Index, VAS pain Visual Analogue Scale pain, VASg Visual Analogue Scale global disease activity
Data are expressed as mean ± SD. The Friedman repeated measures test and Dunn's multiple comparison test were used * p < 0.0001 vs T0, **p < 0.001 vs T0,
***p < 0.01 vs T0
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In accordance with other reports, the main outcome
measures of our study were disease-related clinical pa-
rameters and subjective indices, such as the BASDAI,
the BASFI and the BASMI scores. An improvement was
noted in disease activity, mobility, and function that was
largely maintained in our responders over the 5-year
study period. While improvement peaked at 6 M, it was
already noticeable at 3 M. In contrast to Baraliakos et al.
who described a slight functional decline during long
observations periods [27], a modest although continuous
improvement was noted in our patients throughout the
study period (Fig. 2). As far as Baraliakos’ patients are
concerned [27], the decline that was noted may have
been linked to a decrease in the proportion of patients
in partial remission noted during the last year of that
study and the progressive structural damage that was
taking place over the study period [27, 33]. Interestingly,
the patients with a slight increase in BASFI scores at the
end of the study were found to have more radiographic
damage [27]. The significance of radiographic damage in
AS has recently been studied by some authors who re-
ported that anti-TNFα does not seem to have important
effects on radiographic progression in these patients
[34]. It is impossible to exclude the existence of a bias
linked to other concurrent treatments, such as NSAIDs,
physical therapy and/or rehabilitation. Intensive rehabili-
tation seems, in fact, to have a synergistic effect in AS
when it is associated to TNFα, producing positive effects
on pain, function, quality of life and disability [33, 35].
In our study, the fall in the responders in CRP and ESR
levels, parameters considered important inflammatory
markers, followed a decrease in disease activity indices.
BASFI and BASDAI scores showed ongoing improve-
ment throughout the 5-year study period (Table 2, Fig. 2).
The persistent effectiveness of infliximab, already notice-
able at 6 M, was confirmed by the BASDAI 50, the ASAS
20, the ASAS 40, and the ASAS 5/6 scores also at the end
of the study. Our results are in agreement with those de-
scribed by Danish investigators who found a rapid, sus-
tained decrease in disease activity in AS patients being
treated with TNFα inhibitors within 6 months of treat-
ment onset [36]. The infliximab survival rate was high, in
our study reaching 50 %. Interestingly, those same parame-
ters showed an opposite trend in the non-responders: after
an initial improvement, the BASFI and BASDAI began to
rise in the non-responders while the ESR and PCR values
remained at higher although stable levels compared to
those in the responders (Fig. 2). Our data support the
hypothesis that disease activity indices and inflamma-
tory markers are predictors of patients’ clinical response
to anti-TNFα treatment and could be useful when pa-
tients with a negative response are being evaluated for
discontinuation.
Therapy in our patients was mostly discontinued for
reasons linked to infusion-related reactions (n = 12;
34.3 %), loss of efficacy (n = 12; 34.3 %) or to several side
effects (n = 7; 20 %) rather than to minor side effects/mild
infections. In accordance with data collected by our center
regarding SpA patients taking other biologic agents, some
of the participants in the present study developed mild in-
fections [37]. Serious infections were, instead, noted in 5
of the As patients participating in the present study: two
developed bronchopneumonia requiring hospitalization,
two developed serious skin infections (of the scalp and/or
severe folliculitis), and one developed a tubular abscess
with serious vaginitis. After discontinuing infliximab ther-
apy for a brief period, all except for the two patients who
presented infection of the scalp and tubular abscess were
able to resume treatment. The drug’s safety was similar to
that described in previous studies [27, 38, 39]. Our results
Table 3 Data concerning infections in the patients studied
during the five year study period
Most frequently reported infections in 5 years study
population (n = 70 patients)
N (%)
Upper respiratory tract infections
(rhinosinusitis, pharyngitis, laryngitis, colds)
13 (18.6 %)
Bronchitis/bronchopneumonia 6 (8.6 %)
Conjunctivitis eye disorders 5 (7.1 %)
Influenza episodes 4 (5.7 %)
Diarrhea 4 (5.7 %)
Urinary infections 4 (5.7 %)
Otitis 2 (2.8 %)
Severe skin infections 2 (2.8 %)
Dental infections 2 (2.8 %)
Vaginitis 1 (1.4 %)
Herpes labialis 1 (1.4 %)
Tubal ascess 1 (1.4 %)
Fig. 4 Infliximab survival (percentage responders) over the 5-year
study. “Cum” survival = cumulative survival
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have confirmed that when first line treatment fails
switching to another biotechnological drug can be an
effective solution and they are in agreement with our
previous retrospective study conducted on a total of
1619 SpA patients treated with infliximab (35.3 %), eta-
nercept (43.7 %) and adalimumab (20.9 %) [40]. Out of
the switchers, there were only 19 AS patients receiving
infliximab as their first anti-TNFα drug and that study
showed that patients who failed to respond to the first
agent often responded to a second-line drug regardless
of the reason for switching.
Conclusion
Study results indicated that infliximab therapy elicited a
beneficial, long-term, safe effect in AS patients over the
5-year study period. Patient amelioration was confirmed
by a marked, persistent improvement in both subjective
and objective disease activity. Study data also suggested
that the female gender, elevated prednisone intake
(>5 mg/day), high VASg levels at baseline, no fall in in-
flammatory indices, persistently high BASFI and BASDAI
levels can all be considered predictors of future anti-TNFα
treatment discontinuation. This study has, of course, some
limitations: most importantly, the study population is
small. In addition, since the patients needed to fulfill the
New York criteria, only those individuals with a relatively
advanced disease form were included. As a consequence,
its results cannot be applied to patients with early, non-
radiographic axial SpA. The study did produce one ori-
ginal finding: that simple clinical/laboratory markers of
disease activity can already predict at baseline which AS
patients are most likely to have a poor response to treat-
ment. This information could, of course, be useful to spe-
cialists who are managing AS patients and further studies
are warranted to confirm these data.
Key messages
 The clinical impact of AS is severe and its
progression leads to disability
 With appropriate treatment, patients with AS can
live relatively normal, independent lives
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